North Carolina is currently home to 2644 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: AdventHealth Infusion Center Asheville, Asheville, North Carolina
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
NCT02690545
Recruiting
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding those bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
10/28/2024
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
Conditions: Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Register for Updates
Embo Registry; National Registry for Artery Embolization
NCT06477965
Recruiting
Embo Registry is a retrospective and prospective observational study to evaluate real world effectiveness and the use of Artery Embolization as a treatment for chronic pain with patients that have osteoarthritis and localized pain to provide symptomatic relief. This study is to determine the efficacy and validity of procedure and that following procedure patients had decreased pain and improved quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Vascular Solutions of North Carolina, Cary, North Carolina
Conditions: Chronic Pain, Osteoarthritis, Knee, Osteoarthritis Thumb, Osteoarthritis Shoulder, Pain, Chronic, Tendonitis Elbow, Tendonitis Shoulder, Tendonitis;Achilles, Tenosynovitis
Register for Updates
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
NCT05927428
Recruiting
The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Wilmington Eye, Leland, North Carolina
Conditions: Neurotrophic Keratitis
Register for Updates
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348
Recruiting
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Novant Health Cancer Institute, Charlotte, North Carolina
Conditions: Multiple Myeloma
Register for Updates
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
NCT06305299
Recruiting
The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration. The study team wants to know how much (dose) of the iC9-CAR.B7-H3 T cells are safe to use in... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
Register for Updates
Supervised Exercise as a Therapeutic Strategy for Interstitial Cystitis/Bladder Pain Syndrome
NCT05699551
Recruiting
In this study, the efficacy of exercise to improve interstitial cystitis/bladder pain syndrome symptoms and quality of life will be investigated.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
10/23/2024
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Register for Updates
Implantation Of Vaginal Construct For Patients With Vaginal Aplasia
NCT05675722
Recruiting
In this Phase 1, single site, clinical trial, Vulvar/vaginal Smooth muscle cells (SMC) and Epithelial Cells (EPC) are isolated from autologous patient's biopsy
Gender:
FEMALE
Ages:
Between 15 years and 45 years
Trial Updated:
10/23/2024
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Congenital Mullerian Duct Anomaly
Register for Updates
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer
NCT04270149
Recruiting
This is a phase I study looking at the safety of cancer peptides combined with adjuvant and GM-CSF in subjects with estrogen receptor (ESR) positive breast cancer. The primary objective of the study is to determine the safety of of the peptide vaccine. The secondary objective is to evaluate the immune response to the vaccine. The peptides used in this vaccine are derived from the estrogen receptor and are combined with the adjuvant Montanide ISA and GM-CSF to enhance their immune response. A pep... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Breast Cancer
Register for Updates
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
NCT04083495
Recruiting
This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study participants and the immune T cells will be separated. T cells will be genetically modified in a laboratory at UNC-Chapel Hill to enable them to produce CD30 antibody. The modified T cells, called ATLCAR.CD30, will be able to target and attach to lymphoma cancer cells that carry the CD30 antigen. Once they are att... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/23/2024
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina
Conditions: Peripheral T Cell Lymphoma
Register for Updates
Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery
NCT06271265
Recruiting
This Phase 1, multicenter, open-label, randomized, bupivacaine-controlled study is designed to evaluate the pharmacokinetics (PK) and safety of EXPAREL vs. bupivacaine HCl for postsurgical analgesia in pediatric subjects aged 0 to less than 6 years of age undergoing cardiac surgery, utilizing local infiltration analgesia (LIA).
Gender:
ALL
Ages:
Between 0 years and 6 years
Trial Updated:
10/22/2024
Locations: Duke University Health System, Durham, North Carolina
Conditions: Postoperative Pain
Register for Updates
Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment
NCT05327062
Recruiting
The objective of this prospective, multicenter controlled study is to assess the feasibility of a patient-tailored implantation by creating a cloud-based pre-procedural multimodality CRT-roadmap by integration of 3D images from 3D activation sequence from ECG, and coronary venous anatomy from cardiac computed tomography. This CRT-roadmap will be used to guide LV lead placement to a coronary vein in an electrically late-activated region. Study Hypothesis: At least 75% of patients undergoing a CR... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Cardiac Resynchronization Therapy, Chronic Heart Failure, Left Bundle-Branch Block
Register for Updates